Vertex Pharmaceuticals Incorporated with ticker code (VRTX) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $578.00 and $325.00 with the average share target price sitting at $458.26. (at the time of writing). Given that the stocks previous close was at $417.88 this would indicate that there is a potential upside of 9.7%. The 50 day moving average now sits at $411.38 and the 200 day moving average is $365.98. The company has a market capitalization of 109.85B. The stock price for the company is currently $426.29 USD
The potential market cap would be $120,462,340,860 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 30.67, revenue per share of $38.30 and a 13.21% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
